Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Journal article
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
Sacubitril/valsartan in Peritoneal Dialysis – Lessons from a Pharmacokinetic Study
Report
Judge P., (2023)
Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery
Preprint
Wijesurendra RS. et al, (2023)
Randomised controlled trials for mpox in endemic countries.
Journal article
Rojek A. et al, (2023), Lancet Infect Dis
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: the DECODE-CKD trial.
Journal article
Bartholdy KV. et al, (2022), Kidney360
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
Journal article
HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology
Empagliflozin in Patients with Chronic Kidney Disease
Journal article
HERRINGTON W. et al, (2022), New England Journal of Medicine
Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials
Journal article
HERRINGTON W. et al, (2022), The Lancet
Determining the Relationship between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights from Genetic Epidemiology
Journal article
HERRINGTON W. et al, (2022), Hypertension
The Health and Care Act 2022: key challenges and priority actions for embedding research in the NHS
Other
HAYNES R., (2022), The Lancet
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Journal article
LANDRAY M. et al, (2022), The Lancet
DETERMINANTS OF POST-OPERATIVE ATRIAL FIBRILLATION IN 1613 PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING IN THE STATIN THERAPY IN CARDIAC SURGERY (STICS) TRIAL
Journal article
Wijesurendra R. et al, (2022), HEART, 108, A61 - A62
Allocated but not treated: the silent 16% - Authors' reply.
Other
Horby P. et al, (2022), Lancet, 399, 1775 - 1776
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomisation study
Preprint
Donovan K. et al, (2022)
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
Journal article
Parish S. et al, (2022), Eur Heart J
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Journal article
HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Journal article
HERRINGTON W., (2022), Nephrology, Dialysis and Transplantation
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Preprint
RECOVERY Collaborative Group None. et al, (2022)